Pharmacogenetics of antipsychotics (Q33836837)

29 July 2017

title

Pharmacogenetics of antipsychotics (English)

1 reference

29 July 2017

1

Eva J Brandl

1 reference

29 July 2017

James L Kennedy

2

1 reference

29 July 2017

Daniel J Müller

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

Canadian Journal of Psychiatry

29 July 2017

published in

1 reference

29 July 2017

volume

59

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

76-88

1 reference

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Using a pharmacogenomic algorithm to guide the treatment of depression

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Haematological toxicity of clozapine and some other drugs used in psychiatry.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genetics of Antipsychotic-induced Side Effects and Agranulocytosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genome-wide association study of antipsychotic-induced QTc interval prolongation

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Clozapine-induced agranulocytosis and its genetic determinants

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Genetics of antipsychotic treatment emergent weight gain in schizophrenia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Pharmacogenetics, drug-metabolizing enzymes, and clinical practice

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Clinical implications of pharmacogenomics for tardive dyskinesia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Half a century of antipsychotics and still a central role for dopamine D2 receptors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Antipsychotic-induced weight gain: a comprehensive research synthesis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Cytochrome P4502D6 genotype does not determine response to clozapine

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology

4 July 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Olanzapine: concordant response in monozygotic twins with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Clozapine and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Is pharmacogenetic CYP2D6 testing useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Risperidone plasma levels, clinical response and side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

CYP2D6 polymorphisms and atypical antipsychotic weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

MDR1 gene polymorphisms and response to acute risperidone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Correlates of response to Olanzapine in a North Indian Schizophrenia sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Functional Consequences of two HTR2C Polymorphisms Associated with Antipsychotic-Induced Weight Gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

SNAP-25 gene polymorphisms and weight gain in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

The catechol-O-methyl-transferase gene in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4079237

Familial occurrence of tardive dyskinesia

29 October 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

Association study of MC4R with complex obesity and replication of the rs17782313 association signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/070674371405900203

The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients

21 January 2018

1 reference

12 December 2020

Association between clozapine response and allelic variation in the 5-HT2C receptor gene

1 reference

12 December 2020

Monozygotic twins concordant for response to clozapine

1 reference

12 December 2020

Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients

1 reference

12 December 2020

Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia

1 reference

12 December 2020

Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients

1 reference

12 December 2020

The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients

1 reference

12 December 2020

Variants in the oxytocin gene and risk for schizophrenia

1 reference

12 December 2020

Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia

1 reference

12 December 2020

Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis

1 reference

12 December 2020

Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia

1 reference

12 December 2020

Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens

1 reference

12 December 2020

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms

1 reference

12 December 2020

Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients

1 reference

12 December 2020

Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene

1 reference

12 December 2020

Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia

1 reference

12 December 2020

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

1 reference

12 December 2020

Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine

1 reference

12 December 2020

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

1 reference

12 December 2020

CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic Patients

1 reference

12 December 2020

HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia

1 reference

12 December 2020

10.1177/070674371405900203

Identifiers

DOI

0 references

PMC publication ID

4079237

1 reference

29 July 2017

1 reference